Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema

INTRODUCTION: Administration of human C1 esterase inhibitor (Berinert(®) P) from target import is the most widespread treatment strategy for patients with hereditary angioedema (HAE). However, a therapeutic health program including Ruconest(®) (conestat alfa) could shorten a patient's expectanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawalec, Paweł, Holko, Przemysław, Paszulewicz, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834719/
https://www.ncbi.nlm.nih.gov/pubmed/24278067
http://dx.doi.org/10.5114/pdia.2013.35616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834719/
https://www.ncbi.nlm.nih.gov/pubmed/24278067
http://dx.doi.org/10.5114/pdia.2013.35616

Ejemplares similares